Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-α2a and erythropoietin-β;Immuntherapie des metastasierten nierenzellkarzinoms mit interleukin-2, interferon-α2a und erythropoetin-β

Urologe - Ausgabe A

Volumn 46, Issue 5, 2007, Pages 528-534

  Schenck, M ^a   Borgermann C ^a   Jager T ^a   Vom Dorp, F ^a   Sperling, H ^b   Rubben H ^a   Lummen G ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b KLINIKEN MARIA HILF GMBH   (Germany)

Author keywords

Epoetin ; Interferon ; Interleukin 2; Metastatic renal cell carcinoma

Indexed keywords

ALPHA2A INTERFERON; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 2;

ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; CORRELATION COEFFICIENT; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINOMETRY; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; QUALITY OF LIFE;

EID: 34248399645     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1313-x     Document Type: Article

References (30)

1. Atkins MB, Regan M, McDermott D (2004) Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10: 6342-6346
2. Atzpodien J, Lopez Hanninen E, Kirchner H et al. (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alpha-2 in progressive metastatic RCC. J Clin Oncol 13: 497-501
3. Blay J, White TD, Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57: 2602-2605
4. Bokemeyer C, Aapro MS, Courdi A et al. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40: 2201-2216
5. Chow W-H, Devesa SS, Warren JL, Fraumeni JF (1999) Rising incidence of renal cell cancer in the United States. JAMA 281: 1628-1631
6. Coppin C, Porzsolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 25: 1-98
7. Daneryd P, Svanberg E, Korner U et al. (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant Erythropoietin: A randomized prospective study. Cancer Res 58: 5374-5379
8. Dutcher JP, Fisher RI, Weiss G (1997) Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: Five year follow-up of the Cytokine Working Group study. Cancer J Sci Am 3: 157-162
9. Geertsen PF, Gore ME, Negrier S et al. (2004) Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer 90: 1156-1162
10. Henke M, Laszig R, Rube C et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260
11. Höckel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28: 36-41
12. Jakobsen EB, Eickhoff JH, Andersen JP, Ottesen M (1994) Perioperative blood transfusion does not affect survival after operation for renal cell cancer. Eur Urol 26: 145-148
13. Janik JE, Sznol M, Urba WJ et al. (1993) Erythropoietin production - A potential marker for interleukin-2 / interferon-responsive tumors. Cancer 72: 2656-2659
14. Leyland-Jones B (2003) BEST Investigators and Study Group. Breast cancer trial with erythropoietin - terminated unexpectedly. Lancet Oncol 4: 459-460
15. Lind M, Vernon C, Cruickshank D et al. (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86: 1243-1249
16. Lissoni P, Rovelli F, Baiocco N et al. (2001) A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res 21: 777-779
17. Lümmen G, Sperling H, Bex A et al. (1998) Modern concepts in the therapy of urinary tract (kidney, ureter, bladder and prostate) tumours. Pharmacol Res 38: 151-164
18. Mancuso A, Sternberg CND (2005) What's new in the treatment of metastatic kidney cancer? BJU Int 95: 1171-1180
19. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
20. Morere JF, Bouillet T, Piperno-Neumann S et al. (1997) Treatment of advanced kidney cancer using recombinant erythropoietin. Prog Urol 7: 399-402
21. Motzer RJ, Bacik J, Schwartz LH et al. (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463
22. Motzer RJ, Rini BI, Bukowski RM et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 1295: 2516-2524
23. Negrier S, Escudier B, Lasset C et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278
24. Nseyo UO, Williams PD, Murphy GP (1986) Clinical significance of erythropoietin levels in renal carcinoma. Urology 28: 301-306
25. Rubins JR (1995) Metastatic renal cell carcinoma: response to treatment with human recombinant Erythropoietin. Ann Intern Med 122: 676-677
26. Rubins JR (1999) Recombinant human Erythropoietin in advanced renal cell carcinoma. 55 Annual Meeting of the ASCO, 1999, p 1357
27. Stadler P, Becker A, Feldmann HJ et al. (1999) Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiation Oncol Biol Phys 44: 749-754
28. Sungur C (1995) Renal cell carcinoma and Erythropoietin. Ann Intern Med 123: 732-733
29. Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657
30. Wirth MP (1993) Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295